Comparison
Myricetin vs Fisetin
GDA workhorse (Myricetin) vs. the senolytic headliner (Fisetin): both polyphenols, wildly different targets.
Myricetin
Polyphenolic Flavonol / Glucose Disposal Adjunct
Fisetin
Senolytic Flavonoid
Effectiveness Profile
At a Glance
| Myricetin | Fisetin | |
|---|---|---|
| Type | Supplement | Longevity |
| Legal status | OTC | OTC |
| Half-life | 2–4 hours (parent); 4–10 hours (conjugates) | ~3 hours (parent compound) |
| Preferred route | Oral | Oral |
| Dose frequency | twice-daily | custom |
| Beginner dose | 250–500 mg | 500–1000 mg |
| Intermediate dose | 500–1000 mg | 1500–2000 mg |
| Advanced dose | 1000–1500 mg | 2000–3000 mg |
| Cycle length | 4–52 wks | 1–52 wks |
| Bioavailability | 5% | 10% |
| Time to peak | 1.5h | 0.75h |
| Active duration | 6h | 6h |
| Storage | Room temperature, dry, protected from light; do not store in aqueous solution (oxidizes within hours) | Room temperature, dry, protected from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Myricetin wins for broad-spectrum metabolic support, adjunctive GDA action with berberine/R-ALA, and handling oxidative or inflammatory load from oral AAS or high-carb meals. It has clear synergy in glucose disposal stacks but rarely stands alone.
Fisetin wins for targeted senolytic potency, clinical evidence for reducing senescent cell burden, and apparent longevity/recovery benefits in looksmaxxing and anti-aging protocols. The "hit-and-run" pulse modality is both unique and convenient, with more user-reported impact on skin, inflammation, and joint recovery over time.
Pick A or B?
Pick Myricetin if:
- The protocol calls for glucose disposal support around carb-heavy meals or refeeds
- Adjunct hepatoprotection and ROS mitigation are needed on an oral-heavy cycle
- The polyphenol slot in a longevity or cardiometabolic stack is open but quercetin/fisetin are already covered
- A mild, stackable GDA is desired without moving the needle on hormones
- Berberine and R-ALA form the GDA base and another mechanistic angle is welcome
Pick Fisetin if:
- Targeting senescent cell clearance or mitigating "inflammaging" is the priority
- Anti-aging, skin rejuvenation, or long-term joint health are stacked goals
- The protocol rotates monthly senolytic pulses for systemic cleanup (AFFIRM protocol)
- An oral, OTC, non-hormonal compound with clinical data is favored
- Synergy is sought with quercetin for a comprehensive senolytic effect